Wuxi AppTec Co Ltd (WUXIF)
7.49
0.00 (0.00%)
USD |
OTCM |
Dec 13, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 21.63B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -35.43% |
| Valuation | |
| PE Ratio | 19.54 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.098 |
| Price to Book Value | 2.749 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.1392 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1067 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services through the discovery, development, and manufacturing spectrum for small-molecule drugs, cell therapies, gene therapies, and testing services for medical devices. Its segments comprise WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It generates the majority of its revenue from the WuXi Chemistry segment. Its geographic areas are the PRC, USA, Europe, and the Rest of the world, in which it generates the majority of its revenue from the USA. |
| URL | https://www.wuxiapptec.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Apr. 29, 2025 (est.) |
| Last Earnings Release | Oct. 28, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 18, 2024 |
Ratings
Profile
| Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services through the discovery, development, and manufacturing spectrum for small-molecule drugs, cell therapies, gene therapies, and testing services for medical devices. Its segments comprise WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It generates the majority of its revenue from the WuXi Chemistry segment. Its geographic areas are the PRC, USA, Europe, and the Rest of the world, in which it generates the majority of its revenue from the USA. |
| URL | https://www.wuxiapptec.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Apr. 29, 2025 (est.) |
| Last Earnings Release | Oct. 28, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 18, 2024 |